Conference Reports for NATAP

Back

Tweet

18th International Workshop on Clinical Pharmacology of Antiviral Therapy June 14-17, 2017 Chicago, Ill.     The 18th International Workshop on Clinical Pharmacology of Antiviral Therapy - Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center Jennifer J. Kiser, Pharm.D. Associate Professor School of Pharmacy University of Colorado at Denver - (07/20/17)   HIGHER DOLUTEGRAVIR PLASMA TROUGH CONCENTRATION (Ctrough) in PATIENTS presenting SIDE EFFECTS : INTEREST of THERAPEUTIC DRUG MONITORING ? - (07/23/17)   MK-3682B Is Not a Clinically Significant CYP3A Inhibitor or Inducer - (07/22/17)   No Clinically Significant Interaction of the Proton Pump Inhibitor Omeprazole With the Components of MK-3682B - (07/22/17)   Small Increase in Dolutegravir Trough, but Equivalent Total Exposure with Simeprevir - (07/22/17)   Dose-selection of odalasvir for use in combination with AL-335 and simeprevir in a phase 2A study using a population pharmacokinetic modelling and simulation approach - (07/22/17)   Lack of clinically significant pharmacokinetic interaction between the 3-DAA combination of AL-335, odalasvir and simeprevir for the treatment of chronic HCV infection and an oral contraceptive containing ethinylestradiol and drospirenone - (07/22/17)   Effect of a high fat meal on the pharmacokinetics of the HIV integrase inhibitor, cabotegravir - (06/26/17)   The Effect of Food on the Pharmacokinetics of the HIV-1 Attachment Inhibitor Temsavir, the Active Moiety of the Prodrug Fostemsavir - (06/26/17)   The Effect of Increased Gastric pH on the Bioavailability of Extended Release Tablet of Fostemsavir in Healthy Subjects / Combinectin-GSK3732394 / 2nd Gen Maturation Inhibitor GSK2838232 - (06/26/17)   Lack of Pharmacokinetic Drug-Drug Interaction Between Norgestimate/Ethinyl Estradiol and Sofosbuvir/Velpatasvir/Voxilaprevir - (06/22/17)   Population Pharmacokinetic Analysis of Voxilaprevir, a Pangenotypic HCV NS3/4A Protease Inhibitor in Hepatitis C Virus-Infected Subjects - (06/22/17)   Evaluation of Drug-Drug Interaction Potential Between Sofosbuvir/Velpatasvir and Atorvastatin - (06/22/17)   A Comparison of the Pharmacokinetics of Dolutegravir in Pregnancy and Postpartum - (06/21/17)   Confirmation of the Drug-drug Interaction Potential Between Cobicistat-boosted Antiretroviral Regimens and Hormonal Contraceptives - (06/21/17)   Lack of Clinically Relevant Effect of Bictegravir on Metformin Pharmacokinetics and Pharmacodynamics - (06/21/17)   The Effect of Hepatic or Renal Impairment on Bictegravir Pharmacokinetics - (06/21/17)   Lack of Effect of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate on Glomerular Filtration Rate in HIV-Infected Patients - (06/21/17)   Effect of cobicistat on tenofovir disoproxil fumarate (TDF) durability: is it time to rethink at TAF trials? - Mark Mascolini (06/21/17)   Evaluation of Drug-Drug Interaction Potential Between Sofosbuvir/Velpatasvir and Atorvastatin - (06/20/17)   Doravirine Does Not Have a Clinically Meaningful Pharmacokinetic Interaction with Elbasvir Plus Grazoprevir - (06/20/17)   Doravirine Does Not Have a Clinically Meaningful Pharmacokinetic Interaction with Ledipasvir/Sofosbuvitr (HARVONI) - (06/20/17)   Evaluation of Drug-Drug Interactions Between Sofosbuvir/Velpatasvir/Voxilapevir and Boosted or Unboosted HIV Antiretroviral Regimens - report 2 - Mark Mascolini - (06/20/17)   Bioequivalence of a Fixed Dose Combination Tablet of Dolutegravir and Rilpivirine in Healthy Subjects - (06/20/17)   Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine-Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis - (06/20/17)   DRUG-DRUG INTERACTIONS OF GLECAPREVIR AND PIBRENTASVIR WITH PRAVASTATIN, ROSUVASTATIN, OR DABIGATRAN ETEXILATE - (06/20/17)   Early Safety, Tolerability and Pharmacokinetic Profile of GSK2838232, a Novel 2nd Generation HIV Maturation Inhibitor, as Assessed in Healthy Subjects - (06/20/17)   Evaluation of Drug-Drug Interactions Between Sofosbuvir/Velpatasvir/Voxilapevir and Boosted or Unboosted HIV Antiretroviral Regimens - (06/20/17)   Effect of cobicistat on tenofovir disoproxil fumarate (TDF) durability: is it time to rethink at TAF trials? - Mark Mascolini - (06/20/17)   High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600mg daily - (06/20/17)   DAAs Glecaprevir and Pibrentasvir Double Levels of Statins and Dabigatran - Mark Mascolini - (06/19/17)   Safety and Concentrations of GSK Maturation Inhibitor With or Without Ritonavir - Mark Mascolini - (06/19/17)   Drug-Carrying Adherence Sensor Does Not Alter Levels of TDF/FTC - Mark Mascolini - (06/19/17)   Dolutegravir Plus Rilpivirine Levels High Enough After Switch From NNRTI - Mark Mascolini - (06/19/17)   Similar Darunavir Levels in CSF With RTV or COBI Boost - Mark Mascolini - (06/19/17)   No Bictegravir Dose Adjustment With Liver or Kidney Impairment - Mark Mascolini - (06/19/17)   COBI-PI Regimens Raise Drospirenone Levels in Oral Contraceptive - Mark Mascolini - (06/19/17)   Dolutegravir Levels Similar in Third Trimester and After Delivery - Mark Mascolini - (06/19/17)   Does TDF Need Dose Reduction When Given With Boosting Agent? - Mark Mascolini - (06/19/17)   Dolutegravir Cmax Higher in Elderly, Tied to Shorter Sleep Duration - Mark Mascolini - (06/16/17)   Evaluation of the Drug-Drug Interaction (DDI) Potential Between Cobicistat-Boosted Protease Inhibitors and Statins - (06/15/17)   Pharmacokinetics of darunavir/cobicistat (DRV/c) and etravirine (ETR) alone and coadministered in HIV-infected patients - (06/15/17)   Clinical Data Support 30 mg Daclatasvir with ATV or ATV/r, 90 mg With Etravirine - Mark Mascolini - (06/15/17)   Statin Levels Much Higher With Cobicistat-Boosted Atazanavir or Darunavir - Mark Mascolini - (06/15/17)   Etravirine Lowers Cobicistat Exposure and Darunavir Trough - Mark Mascolini - (06/15/17)